Please assess the completion status of the following clinical trial:

Trial Title: Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of any of the following for at least 4 weeks:~  * Stage IIIB (with effusions) or stage IV non-small cell lung cancer~ * Extensive stage small cell lung cancer~ * Stage III or IV pancreatic cancer~ * Stage IV liver cancer~ * Stage III or IV gallbladder cancer~ * Stage III or IV bile duct cancer~ * Stage IV esophageal cancer~ * Stage IV gastric cancer~ * Second line stage IV colorectal cancer~* Meets diagnostic and Statistical Manual of Mental Disorders-4th Edition and Endicott criteria for major depressive disorder~* Duration of depressive symptoms ≥ 4 weeks~* Hamilton Depression D 17 (HAM-D 17) Scale ≥ 14~* No active suicidality requiring immediate care or psychiatric hospitalization~PATIENT CHARACTERISTICS:~* Able to swallow pills~* No active substance abuse disorder (including alcohol abuse within the past 6 months), psychotic disorder or active psychotic symptoms, organic mental disorders, or bipolar disorder~* No clinical or laboratory evidence of hypothyroidism~* No hypercalcemia~* No severe anemia, defined as hemoglobin \< 10 g/dL~* No history of multiple adverse drug reactions or allergy to study drugs~* Not pregnant~* No history of head trauma~* No history of epilepsy~PRIOR CONCURRENT THERAPY:~* No other concurrent antidepressant medications or psychostimulants

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo-Placebo (Type: PLACEBO_COMPARATOR): Participants in this arm were randomized to receive placebo once daily for the first 4 weeks and placebo once daily for the second 4 weeks
- Placebo-Escitalopram (Type: OTHER): Participants in this arm were randomized to receive placebo once daily for the first 4 weeks and escitalopram oxalate 10 mg once daily for the second 4 weeks
- Escitalopram-Placebo (Type: OTHER): Participants in this arm were randomzied to receive escitalopram 10 mg once daily for the first 4 weeks and placebo once daily for the second 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).